Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$28.41 ▼ -0.76
(-2.60%)
MKT CAP: $5.87B • VOL: 1.27M
52W L $21 52W H $45
IMVT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-03-31 | FY 2024
FILED 2025-03-31 | FY 2023
FILED 2024-03-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.67B | $1.37B | $856.8M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $0 | $0 | $0 |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$596.6M | -$488.3M | -$306.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$505.6M | -$413.8M | -$259.3M |
| EBITDA (Normalized) | -$596.6M | -$487.7M | -$306.0M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$407.3M | -$375.9M | -$214.2M |
| Capital Expenditures (CapEx) | $8.0K | $759.0K | $0 |
| Free Cash Flow (FCF) | -$407.3M | -$376.6M | -$214.2M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | -11.9% |
| Cash & Short-Term Equivalents | $994.5M | $374.7M | — |
| Total Debt (Short + Long Term) | $29.8M | $30.7M | $787.9M |
| Total Stockholders' Equity | $986.1M | $352.6M | $1.62B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IMVT.